ARV-110 targeting androgen receptor (AR) and ARV-471 targeting estrogen receptor (ER), both of which are developed by Arvinas Inc. (New Haven, CT, USA) to combat prostate cancer and breast cancer, respectively, came into clinical trials in 2019 [132]. This evidence concerns the gene ESR1 and breast cancer.